Literature DB >> 21413978

Predictors of indeterminate IFN-γ release assay in screening for latent TB in inflammatory bowel diseases.

Pavol Papay1, Alexander Eser, Stefan Winkler, Sophie Frantal, Christian Primas, Wolfgang Miehsler, Sieglinde Angelberger, Gottfried Novacek, Andrea Mikulits, Harald Vogelsang, Walter Reinisch.   

Abstract

BACKGROUND: IFN-γ release assays (IGRA), widely used for latent tuberculosis screening prior to anti-TNF-α treatment, are limited by indeterminate results in patients under immunomodulatory (IM) therapy. The aim of our observational study was to delineate factors associated with indeterminate IGRA results.
METHODS: A total of 190 patients with inflammatory bowel disease were included. IGRA was indeterminate if the result of IFN-γ concentration was < 0·35 IU mL(-1) for tuberculosis-specific antigens and < 0·5 IU mL(-1) for the positive control. Predictors for indeterminate results were delineated from multivariate logistic regression.
RESULTS: IFN-γ release assays was indeterminate in 26/190 (13·7%) patients. Indeterminate IGRA were associated with lower serum albumin levels (odds ratio [OR] 0·88, 95% confidence interval [CI] 0·79-0·96), lower absolute lymphocyte count (OR 0·39, 95% CI 0·18-0·75) and double IM therapy (OR 2·98, 95% CI 0·95-8·90). Sub-analysis of IM therapy revealed an association of steroid therapy with indeterminate IGRA (OR 3·19, 95% CI 1·35-7·70). Hypoalbuminaemia increased the risk of indeterminate IGRA by (OR 2·97, 95% CI 1·03-8·61) and lymphopaenia by (OR 3·28, 95% CI 1·41-7·65). After a mean of 18·5 ± 14·4 days, retesting of IGRA in 18 patients with indeterminate results yielded 9 negative vs. 9 indeterminate results.
CONCLUSIONS: Our results reveal associations of indeterminate IGRA with low serum albumin levels and absolute lymphocyte count and double IM therapy. IGRA testing appears best to be performed prior to initiation of IM therapy in patients with inflammatory bowel disease.
© 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21413978     DOI: 10.1111/j.1365-2362.2011.02502.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  14 in total

1.  Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization.

Authors:  Ravy K Vajravelu; Mark T Osterman; Faten N Aberra; Jason A Roy; Gary R Lichtenstein; Ronac Mamtani; David S Goldberg; James D Lewis; Frank I Scott
Journal:  Inflamm Bowel Dis       Date:  2017-12-19       Impact factor: 5.325

2.  IGRA testing in patients with immune-mediated inflammatory diseases: which factors influence the results?

Authors:  Juan González-Moreno; Mercedes García-Gasalla; Inés Losada-López; Carmen Cifuentes Luna; Isabel Mir Viladrich; Victoria Fernández-Baca; Araceli Serrano; Antonio Juan Mas; Joan Riera-Oliver; Antoni Payeras Cifre
Journal:  Rheumatol Int       Date:  2017-10-19       Impact factor: 2.631

3.  Risk factors associated with indeterminate gamma interferon responses in the assessment of latent tuberculosis infection in a high-incidence environment.

Authors:  Tolu Oni; Hannah P Gideon; Nonzwakazi Bangani; Relebohile Tsekela; Ronnett Seldon; Kathryn Wood; Katalin A Wilkinson; Rene T Goliath; Tom H M Ottenhoff; Robert J Wilkinson
Journal:  Clin Vaccine Immunol       Date:  2012-06-20

4.  Analysis of predictors influencing indeterminate whole-blood interferon-gamma release assay results in patients with rheumatic diseases.

Authors:  Hyun-Ju Jung; Tae-Jong Kim; Hyoung-Sang Kim; Young-Nan Cho; Hye-Mi Jin; Moon-Ju Kim; Jeong-Hwa Kang; Ki-Jeong Park; Sung-Ji Lee; Shin-Seok Lee; Yong-Soo Kwon; Dae-Hyun Yoo; Seung-Jung Kee; Yong-Wook Park
Journal:  Rheumatol Int       Date:  2014-05-12       Impact factor: 2.631

5.  Superiority of Interferon Gamma Assay Over Tuberculin Skin Test for Latent Tuberculosis in Inflammatory Bowel Disease Patients in Brazil.

Authors:  Renata F Amorim; Eduardo R C Viegas; Antonio José V Carneiro; Barbara C Esberard; Evelyn S Chinem; Raquel S Correa; Luciana Rodrigues; Marcelo Ribeiro-Alves; Kelly S Silva; Heitor S de Souza; Ana Teresa P Carvalho
Journal:  Dig Dis Sci       Date:  2019-01-23       Impact factor: 3.487

6.  High Proportion of Indeterminate QuantiFERON-TB Gold In-Tube Results in an Inpatient Population Is Related to Host Factors and Preanalytical Steps.

Authors:  Valeria Fabre; Shmuel Shoham; Kathleen R Page; Maunank Shah
Journal:  Open Forum Infect Dis       Date:  2014-09-19       Impact factor: 3.835

7.  The conundrum of indeterminate QuantiFERON-TB Gold results before anti-tumor necrosis factor initiation.

Authors:  Shahrad Hakimian; Yevgeniy Popov; Abbas H Rupawala; Karen Salomon-Escoto; Steven Hatch; Randall Pellish
Journal:  Biologics       Date:  2018-02-27

8.  Evaluating an Education Program to Reduce Indeterminate QuantiFERON Gold In-Tube Results.

Authors:  Saroochi Agarwal; Duc T Nguyen; Justin D Lew; Brenda Campbell; Edward A Graviss
Journal:  Tuberc Res Treat       Date:  2018-10-11

9.  Diagnostic Value of Interferon-γ Release Assays on Pericardial Effusion for Diagnosis of Tuberculous Pericarditis.

Authors:  Sainan Bian; Yueqiu Zhang; Lifan Zhang; Xiaochun Shi; Xiaoqing Liu
Journal:  PLoS One       Date:  2016-10-18       Impact factor: 3.240

10.  Effects of acute critical illnesses on the performance of interferon-gamma release assay.

Authors:  Chun-Ta Huang; Sheng-Yuan Ruan; Yi-Ju Tsai; Ping-Hung Kuo; Shih-Chi Ku; Pei-Lin Lee; Lu-Cheng Kuo; Chia-Lin Hsu; Chun-Kai Huang; Ching-Yao Yang; Ying-Chun Chien; Jann-Yuan Wang; Chong-Jen Yu
Journal:  Sci Rep       Date:  2016-01-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.